Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | January 20, 2026 | January 21, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date January 20, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2036-01-19 | Direct | 16,833 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 16,833 · Balance 16,833 F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2032-08-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F4: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 18,115 · Balance 0 F2: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F4: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 5,468 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F4: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F3: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F4: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 5,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000172 · form_4.xml · derivative · entry 3 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,468 shares Expires 2028-11-20 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F4 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 18,115 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-26-000172 · form_4.xml · derivative · entry 2 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,115 shares Expires 2032-11-20 F2 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F4 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 40,000 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-26-000172 · form_4.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-08-01 F2 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F4 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:07 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001193125-26-269401 · ownership.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 16,833 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001193125-26-018023 · ownership.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,833 Underlying: Common Stock · 16,833 shares Expires 2036-01-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 5,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000412 · form_4.xml · derivative · entry 2 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,583 Underlying: Common Stock · 5,468 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 18,115 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-25-000412 · form_4.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,115 Underlying: Common Stock · 18,115 shares Expires 2032-11-20 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 20:47 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 40,400 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-108119 · ownership.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2035-08-11 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:36 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001415889-25-016969 · form4-06122025_080628.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017204 · form4-06172024_040602.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.